BNP Paribas Financial Markets
AEGR

BNP Paribas Financial Markets’s Aegerion Pharmaceuticals AEGR Stock Holding History

BNP Paribas Financial Markets’s Portfolio AEGR Stock Details AEGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-4,558
Closed -$46K – 3451
2015
Q4 		$46K Sell
4,558
-627
-12% -$7.55K ﹤0.01% 2862
2015
Q3 		$70.5K Buy
5,185
+3,099
+149% +$55.2K ﹤0.01% 2626
2015
Q2 		$39.6K Buy
2,086
+1,393
+201% +$30.1K ﹤0.01% 2633
2015
Q1 		$18.1K Buy
+693
New +$17.6K ﹤0.01% 2412
2014
Q4 		– Sell
-1,771
Closed -$59.1K – 3849
2014
Q3 		$59.1K Buy
1,771
+1,719
+3,306% +$53.4K ﹤0.01% 2494
2014
Q2 		$1.67K Buy
+52
New +$1.94K ﹤0.01% 3207
2014
Q1 		– Sell
-373
Closed -$26.5K – 4092
2013
Q4 		$26.5K Sell
373
-7,989
-96% -$611K ﹤0.01% 2126
2013
Q3 		$717K Sell
8,362
-1,769
-17% -$150K ﹤0.01% 1317
2013
Q2 		$642K Buy
+10,131
New +$538K ﹤0.01% 1327

Other funds holding AEGR

SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

BNP Paribas Financial Markets's AEGR Position: Q1 2016 in Review

BNP Paribas Financial Markets sold out of Aegerion Pharmaceuticals (AEGR) in Q1 2016, closing a stake of 4,558 shares — an estimated $46K sold.

BNP Paribas Financial Markets first reported a position in AEGR in Q2 2013 and held it in 9 quarters. The position peaked at $717K in Q3 2013. 101 funds tracked by Wall St. Rank hold AEGR as of Q1 2016.

  • BNP Paribas Financial Markets reported no remaining Aegerion Pharmaceuticals position as of Q1 2016 after selling out during the quarter.
  • BNP Paribas Financial Markets sold 4,558 Aegerion Pharmaceuticals shares in Q1 2016, an estimated $46K.
  • BNP Paribas Financial Markets first reported a position in Aegerion Pharmaceuticals in Q2 2013 and held it in 9 quarters.
  • BNP Paribas Financial Markets's Aegerion Pharmaceuticals position peaked at $717K in Q3 2013.
  • 101 funds tracked by Wall St. Rank held Aegerion Pharmaceuticals as of Q1 2016.

Based on BNP Paribas Financial Markets's 13F filing for Q1 2016, filed 22 Apr 2016.